Cardiac mass and function, carotid artery intima media thickness, homocysteine and lipoprotein levels in children and adolescents with growth hormone deficiency.

Plain-language guide to PMID 15526719 (2004): controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 10 girls.

Key Facts

PMID: 15526719
Journal: Journal of pediatric endocrinology & metabolism : JPEM
Year: 2004
Study type: Controlled Clinical Trial
Authors: Szczepańiska Kostro J et al. (5 authors)

What This Study Did, in Plain Language

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this controlled clinical trial publication.

The aim of this study was to compare atherosclerotic risk factors in children with GHD and a normal population.

Why It Was Studied

Early atheromatic changes have been found in the carotid and the femoral arteries of young adults with growth hormone (GH) deficiency (GHD).

Who Took Part

According to the abstract, 10 girls were involved.

The age groups tagged for this paper are children and teenagers, both men and women.

Twenty-five patients (10 girls, 15 boys) with GHD qualified for GH replacement treatment were included in the study.

The control group consisted of 22 healthy children (11 girls, 11 boys) with no family history of atherosclerosis and cardiovascular disease.

How the Study Was Run

Cardiac mass and function was evaluated by one-dimensional, two-dimensional echocardiography and the Doppler method.

Common carotid intima-media thickness was measured with a linear probe (7.5 MHz).

Lipid metabolism parameters (total cholesterol, HDL- and LDL-cholesterol, triglycerides), lipoprotein A (Lp(a)) and homocysteine levels were measured.

What Was Measured

The subject headings attached to it are Cardiomegaly, Cardiovascular Diseases, Carotid Arteries, Carotid Artery Diseases, Diastole, Echocardiography and Growth Disorders.

What This Means in Plain Language

This is a controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 10 girls.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 11 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2004 (Journal of pediatric endocrinology & metabolism : JPEM), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.